Table 5

Comparison of patients enrolled in RODIN and the remainder of the cohort

UK-RODIN subjects (n = 88)Non-RODIN subjects (n = 319)P
Inhibitors reported, n (%)
 All33 (37.5)85 (26.7).05
 High titer17 (19.3)43 (13.5).17
 Low titer16 (18.2)42 (13.2).23
Age at first treatment, mo
 Median89
 IQR2-124-14.14
 Range0-520-95
Ethnicity
 White73 (83)281 (88).21
 Nonwhite15 (17)38 (12)
FVIII mutation
 High risk54 (61.4)190 (59.6)
 Low risk31 (35.2)102 (32).79
 Not known3 (3.4)27 (8)
Intensive treatment at first exposure, n (%)
 Yes19 (21.6)37 (11.6).02
 No69 (78.4)274 (85.9)
 Not known0 (0.0)8 (2.5)
Intensive treatment during first 50 EDs (excluding first exposure), n (%)
 Yes40 (45.5)135 (42.3).82
 No48 (54.5)171 (53.6)
 Not known0 (0.0)13 (4.1)
 FH of a FVIII inhibitor15 (17.05)26 (8.15).03
Peak inhibitor titer
 Median55
 IQR2. 0-29.21.13-17.9.86
 Range0.07-2220.3-1562
EDs to inhibitor formation
 Median16.515
 IQR8.75-31.75(9-29).93
 Range3-358[1-442]
Follow up for patients not developing an inhibitor, mo
 Median48.044.3
 IQR30.0-69.024.0-60.0.58
 Range6.0-142.51.6-154.5